Envestnet Portfolio Solutions Inc. Acquires 6,729 Shares of Danaher Co. (NYSE:DHR)

Envestnet Portfolio Solutions Inc. boosted its position in Danaher Co. (NYSE:DHR - Free Report) by 12.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,211 shares of the conglomerate's stock after buying an additional 6,729 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Danaher were worth $13,929,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. BKM Wealth Management LLC purchased a new position in shares of Danaher during the 4th quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher during the 4th quarter worth $29,000. OFI Invest Asset Management bought a new stake in shares of Danaher in the 3rd quarter worth about $30,000. Rakuten Securities Inc. acquired a new stake in shares of Danaher in the 4th quarter valued at about $36,000. Finally, Financial Connections Group Inc. bought a new position in shares of Danaher during the fourth quarter worth about $41,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares of the company's stock, valued at $1,029,891.48. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Danaher news, Director Alan G. Spoon sold 708 shares of the business's stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now owns 116,202 shares in the company, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the firm's stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company's stock, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,984 shares of company stock worth $25,997,094. Corporate insiders own 11.10% of the company's stock.

Danaher Price Performance

Shares of NYSE DHR traded up $1.95 during mid-day trading on Friday, reaching $253.38. 1,520,786 shares of the company traded hands, compared to its average volume of 2,798,414. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The firm has a market cap of $187.68 billion, a PE ratio of 42.95, a price-to-earnings-growth ratio of 3.90 and a beta of 0.83. The stock has a fifty day simple moving average of $248.07 and a 200-day simple moving average of $234.03. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm's revenue for the quarter was down 2.6% on a year-over-year basis. During the same period last year, the firm earned $2.36 EPS. Equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 28th. Danaher's payout ratio is 18.31%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DHR. TD Cowen boosted their price target on Danaher from $280.00 to $290.00 and gave the company a "buy" rating in a report on Wednesday, April 24th. HSBC upgraded Danaher from a "hold" rating to a "buy" rating and increased their price target for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Citigroup boosted their price objective on Danaher from $280.00 to $290.00 and gave the company a "buy" rating in a research report on Wednesday, April 24th. KeyCorp raised their target price on Danaher from $260.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, February 1st. Finally, Robert W. Baird boosted their price target on shares of Danaher from $259.00 to $271.00 and gave the company an "outperform" rating in a report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $267.31.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.